Qyuns Therapeutics Past Earnings Performance
Past criteria checks 0/6
Qyuns Therapeutics's earnings have been declining at an average annual rate of -70.3%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 52.7% per year.
Key information
-70.3%
Earnings growth rate
-47.2%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | 52.7% |
Return on equity | -173.2% |
Net Margin | -3,442.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Qyuns Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 15 | -508 | 165 | 364 |
30 Sep 23 | 13 | -476 | 167 | 331 |
31 Dec 22 | 10 | -298 | 77 | 257 |
31 Dec 21 | 21 | -298 | 49 | 152 |
Quality Earnings: 2509 is currently unprofitable.
Growing Profit Margin: 2509 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2509's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2509's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2509 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 2509 has a negative Return on Equity (-173.2%), as it is currently unprofitable.